Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424440 | 0.83 | NUDT1 (0.48) | KDM4EALDH1A1LMNATSHR | |
| SCHEMBL3425595 | 0.80 | KEAP1 (0.58) | IKBKBCHUKKDM4EALDH1A1GAA | |
| SCHEMBL30050554 | 0.80 | KEAP1 (0.58) | IKBKBCHUKKDM4EALDH1A1GAA | |
| SCHEMBL1442009 | 0.78 | PDPK1 (0.59) | IKBKBCHUKKEAP1CHEK1PDPK1 | |
| SCHEMBL29800264 | 0.78 | PDPK1 (0.59) | IKBKBCHUKKEAP1CHEK1PDPK1 | |
| SCHEMBL20542164 | 0.77 | PIM3 (0.44) | IKBKBCHUKCDK8PIM1PIM3 | |
| SCHEMBL30136593 | 0.77 | KEAP1 (0.64) | KDM4EPIM1PIM3KEAP1LMNA | |
| Hydrochloric Acid SCHEMBL1440567 | 0.77 | PDPK1 (0.57) | IKBKBCHUKKEAP1CHEK1PDPK1 | |
| SCHEMBL761721 | 0.77 | KEAP1 (0.64) | KDM4EPIM1PIM3KEAP1LMNA | |
| SCHEMBL30410090 | 0.75 | TSHR (0.51) | KDM4EALDH1A1GLAGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110891935-B | Bicyclic compounds and their use in cancer treatment | 泰普斯特医疗公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2014210255-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | IKBKB 161/4885CHUK 43/4885KDM4E 1723/4885 |
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | IKBKB 161/4885CHUK 43/4885KDM4E 1723/4885 |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | IKBKB 161/4885CHUK 43/4885KDM4E 1723/4885 |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | IKBKB 58/4885CHUK 21/4885KDM4E 591/4885 |
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | IKBKB 1238/4885CHUK 255/4885KDM4E 959/4885 |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | IKBKB 143/4885CHUK 40/4885KDM4E 1683/4885 |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | IKBKB 143/4885CHUK 40/4885KDM4E 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.